These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
338 related articles for article (PubMed ID: 38016356)
41. Prostaglandin F Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995 [TBL] [Abstract][Full Text] [Related]
42. Near-infrared light-mediated nanoplatforms for cancer thermo-chemotherapy and optical imaging. Zhang Z; Wang J; Chen C Adv Mater; 2013 Jul; 25(28):3869-80. PubMed ID: 24048973 [TBL] [Abstract][Full Text] [Related]
43. Role of Dicer in regulating oxaliplatin resistance of colon cancer cells. Lai HH; Lin LJ; Hung LY; Chen PS Biochem Biophys Res Commun; 2018 Nov; 506(1):87-93. PubMed ID: 30336979 [TBL] [Abstract][Full Text] [Related]
44. Acquired and intrinsic gemcitabine resistance in pancreatic cancer therapy: Environmental factors, molecular profile and drug/nanotherapeutic approaches. Ashrafizadeh M; Luo K; Zhang W; Reza Aref A; Zhang X Environ Res; 2024 Jan; 240(Pt 2):117443. PubMed ID: 37863168 [TBL] [Abstract][Full Text] [Related]
45. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Gao R; Fang C; Xu J; Tan H; Li P; Ma L Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170 [TBL] [Abstract][Full Text] [Related]
46. Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. Zhao X; Yang K; Zhao R; Ji T; Wang X; Yang X; Zhang Y; Cheng K; Liu S; Hao J; Ren H; Leong KW; Nie G Biomaterials; 2016 Sep; 102():187-97. PubMed ID: 27343466 [TBL] [Abstract][Full Text] [Related]
47. Role of nanostructures in improvising oral medicine. Ghosh S; Ghosh S; Sil PC Toxicol Rep; 2019; 6():358-368. PubMed ID: 31080743 [TBL] [Abstract][Full Text] [Related]
48. Nanobiotechnological approaches in osteosarcoma therapy: Versatile (nano)platforms for theranostic applications. Jiang Y; He K Environ Res; 2023 Jul; 229():115939. PubMed ID: 37088317 [TBL] [Abstract][Full Text] [Related]
49. Doxorubicin-loaded graphene oxide nanocomposites in cancer medicine: stimuli-responsive carriers, co-delivery and suppressing resistance. Ashrafizadeh M; Saebfar H; Gholami MH; Hushmandi K; Zabolian A; Bikarannejad P; Hashemi M; Daneshi S; Mirzaei S; Sharifi E; Kumar AP; Khan H; Heydari Sheikh Hossein H; Vosough M; Rabiee N; Kumar Thakur V; Makvandi P; Mishra YK; Tay FR; Wang Y; Zarrabi A; Orive G; Mostafavi E Expert Opin Drug Deliv; 2022 Apr; 19(4):355-382. PubMed ID: 35152815 [TBL] [Abstract][Full Text] [Related]
50. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
51. Circular RNA circ_0032821 contributes to oxaliplatin (OXA) resistance of gastric cancer cells by regulating SOX9 via miR-515-5p. Zhong Y; Wang D; Ding Y; Tian G; Jiang B Biotechnol Lett; 2021 Feb; 43(2):339-351. PubMed ID: 33123829 [TBL] [Abstract][Full Text] [Related]
52. A Chinese herbal Formula, Chang-Wei-Qin, Synergistically Enhances Antitumor Effect of Oxaliplatin. Zhang Y; Zhang Q; Fan Z; Sun J; Liu X; Cheng L; Li A; Xu J Pathol Oncol Res; 2015 Apr; 21(2):389-97. PubMed ID: 25103530 [TBL] [Abstract][Full Text] [Related]
53. The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology. Lin X; Xu L; Tan H; Zhang X; Shao H; Yao L; Huang X Heliyon; 2022 Nov; 8(11):e11305. PubMed ID: 36353164 [TBL] [Abstract][Full Text] [Related]
54. METTL3 promotes drug resistance to oxaliplatin in gastric cancer cells through DNA repair pathway. Wang Y; Hong Z; Song J; Zhong P; Lin L Front Pharmacol; 2023; 14():1257410. PubMed ID: 37822880 [TBL] [Abstract][Full Text] [Related]
55. Multifunctional nanoplatforms co-delivering combinatorial dual-drug for eliminating cancer multidrug resistance. Wei X; Song M; Li W; Huang J; Yang G; Wang Y Theranostics; 2021; 11(13):6334-6354. PubMed ID: 33995661 [TBL] [Abstract][Full Text] [Related]
56. Metformin increases the cytotoxicity of oxaliplatin in human DLD-1 colorectal cancer cells through down-regulating HMGB1 expression. Huang WS; Lin CT; Chen CN; Chang SF; Chang HI; Lee KC J Cell Biochem; 2018 Aug; 119(8):6943-6952. PubMed ID: 29737584 [TBL] [Abstract][Full Text] [Related]
57. Modulating tumor immunity by metronomic dosing of oxaliplatin incorporated in multiple oral nanoemulsion. Choi JU; Maharjan R; Pangeni R; Jha SK; Lee NK; Kweon S; Lee HK; Chang KY; Choi YK; Park JW; Byun Y J Control Release; 2020 Jun; 322():13-30. PubMed ID: 32169534 [TBL] [Abstract][Full Text] [Related]
58. Recent Advances in Nanoparticle-Based Co-Delivery Systems for Cancer Therapy. Al Bostami RD; Abuwatfa WH; Husseini GA Nanomaterials (Basel); 2022 Aug; 12(15):. PubMed ID: 35957103 [TBL] [Abstract][Full Text] [Related]
59. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Plasencia C; Martínez-Balibrea E; Martinez-Cardús A; Quinn DI; Abad A; Neamati N Int J Oncol; 2006 Jul; 29(1):225-35. PubMed ID: 16773204 [TBL] [Abstract][Full Text] [Related]
60. ATB Chen Z; Chen H; Huang L; Duan B; Dai S; Cai W; Sun M; Jiang Z; Lu R; Jiang Y; Jiang X; Zheng H; Yao Q; Kim K; Lin G; Xie C; Chu M; Chen R; Kou L Int J Pharm; 2023 Jun; 641():123082. PubMed ID: 37244464 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]